Obesity

all catalysts(0)

nothing on the calendar yet

News(10)

• Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand
  A surge of consolidation, rising appetite for specialized manufacturing and a shift toward decentralized trials is reshaping Switzerland’s life sciences landscape. From peptide producers to organoi…
  biospace · 9h ago
• What it’s like to wait for the call from the Nobel Prize committee
  Ahead of this year's Nobel Prize announcements, STAT chatted with Mary-Claire King, who discovered the BRCA cancer mutations and is frequently mentioned in prize predictions.
  stat · 2d ago
• Access to addiction meds for young people has improved — but retention hasn’t
  Only a small fraction of young people with opioid use disorder receive addiction medications, and few stay on them for long, a study finds.
  stat · 2d ago
• This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
  The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.
  biopharma_dive · 2d ago
• An Ebola treatment center was burned down as the death toll in Congo passes 4,000
  Congo's Ebola outbreak has killed more than 4,000 people, authorities said, as they struggle to contain what has become the fastest-growing Ebola outbreak in history.
  stat · 2d ago
• STAT+: Up and down the ladder: The latest comings and goings
  From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
  stat · 2d ago
• STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and more
  The U.S. approved 10 drugmakers to participate in a 340B pilot program that will allow them to offer rebates, instead of upfront discounts, to certain providers
  stat · 3d ago
• Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
  Kailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic…
  biospace · 3d ago
• #EASD26: Regeneron sees a future combining its obesity drug with lipid-lowering therapy
  MILAN — As more GLP-1-based drugs reach late-stage trials and post stronger and stronger weight loss effects, companies that want to enter the market are looking for differentiating factors. Regene…
  endpoints · 3d ago
• Mistrust in science and a juicy gene-editing lawsuit
  Why have so many Americans lost trust in science? And what's the deal with a new gene-editing lawsuit? Find out on this week's episode of "The Readout LOUD" podcast.
  stat · 3d ago